The Latest Breaking News from Disease

AbbVie Inc (NYSE:ABBV) announced topline results from U-ENDURE Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease. The trial included patients who had an inadequate response or were intolerant to conventional or biologic therapy.  A significantly higher proportion of patients who received upadacitinib 15 mg or 30…

Dengue fever and leptospirosis cases are on the rise in State

Apps on phone can help detect changes in eye, says specialist

Deaths from drug overdoses rose almost 15% in the U.S. last year, topping 100,000 and setting another grim record, according to provisional data from Centers for Disease Control and Prevention.

Making sure you're sleeping in the optimum position helps relieve stress on blood vessels that return the blood to the heart as hypertension is one of the biggest risk factors for cardiovascular disease

Regulus Therapeutics Inc. (NASDAQ: RGLS) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application for RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Scientists have discovered a way to differentiate between people with the disease and tailor their treatment.

NONTHABURI: The National Communicable Diseases Committee has started to discuss post-pandemic plans, including requirements for visitors to keep wearing face masks, according to the public health minister.

The European Union will no longer require masks to be worn at airports and on planes starting next week amid the easing of coronavirus restrictions across the bloc, authorities said Wednesday. The European Union Aviation Safety Agency said it hoped the joint decision, made with the European Center for Disease…

Described as inspirational, Anne was diagnosed with Idiopathic Pulmonary Fibrosis when she was 58 after colleagues at the Royal Liverpool University Hospital noticed her coughing

Development of a new cancer immunotherapy pioneered by Roche was thrown in doubt on Wednesday when its drug tiragolumab failed to slow the progression of lung cancer in a second trial. In a study, a combination of tiragolumab and Roche's established Tecentriq drug did not reduce the rate of disease…